Association between the vasa vasorum and the atherosclerotic changes in cardiac allograft vasculopathy: Volumetric analysis

European Heart Journal Cardiovascular Imaging

Volumn 17, Issue 3, 2016, Pages 272-279

  Park, Kyoung Ha ^a,b   Kwon, Taek Geun ^a   Matsuzawa, Yasushi ^a   Sun, Tao ^a   Liu, Zhi ^a   Lennon, Ryan J ^a   Lerman, Lilach O ^a   Kushwaha, Sudhir S ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

^b Hallym University Medical Center   (South Korea)

Author keywords

cardiac allograft vasculopathy; heart transplantation; vasa vasorum

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLATE MOFETIL; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIAC ALLOGRAFT VASCULOPATHY; CLINICAL ARTICLE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEART TRANSPLANTATION; HUMAN; INTRAVASCULAR ULTRASOUND; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NORMAL DISTRIBUTION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; THICKNESS; VASA VASORUM; AGED; ALLOGRAFT; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; INTERVENTIONAL ULTRASONOGRAPHY; MIDDLE AGED; PATHOLOGY; RISK FACTOR;

AGED; ALLOGRAFTS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; ULTRASONOGRAPHY, INTERVENTIONAL; VASA VASORUM;

EID: 84963940261     PISSN: 20472404     EISSN: 20472412     Source Type: Journal    
DOI: 10.1093/ehjci/jev285     Document Type: Article

References (22)

1. Weis M, von Scheidt W. Cardiac allograft vasculopathy: a review. Circulation 1997; 96: 2069-77
2. Rickenbacher PR, Pinto FJ, Chenzbraun A, Botas J, Lewis NP, Alderman EL, et al. Incidence and severity of transplant coronary artery disease early and up to 15 years after transplantation as detected by intravascular ultrasound. J Am Coll Cardiol 1995; 25: 171-7
3. Kobashigawa JA, Tobis JM, Starling RC, Tuzcu EM, Smith AL, Valantine HA, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-7
4. Williams JK, Heistad DD. Structure and function of vasa vasorum. Trends Cardiovasc Med 1996; 6: 53-7
5. Gossl M, Versari D, Hildebrandt HA, Bajanowski T, Sangiorgi G, Erbel R, et al. Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis. JACC Cardiovasc Imaging 2010; 3: 32-40
6. Kwon HM, Sangiorgi G, Ritman EL, McKenna C, Holmes DR Jr, Schwartz RS, et al. Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-6
7. Rahmani M, Cruz RP, Granville DJ, McManus BM. Allograft vasculopathy versus atherosclerosis. Circ Res 2006; 99: 801-15
8. Colvin-Adams M, Harcourt N, Duprez D. Endothelial dysfunction and cardiac allograft vasculopathy. J Cardiovasc Transl Res 2013; 6: 263-77
9. Tsutsui H, Ziada KM, Schoenhagen P, Iyisoy A, Magyar WA, Crowe TD, et al. Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study. Circulation 2001; 104: 653-7
10. Hernandez JM, de Prada JA, Burgos V, Sainz Laso F, Valls MF, Vilchez FG, et al. Virtual histology intravascular ultrasound assessment of cardiac allograft vasculopathy from 1 to 20 years after heart transplantation. J Heart Lung Transplant 2009; 28: 156-62
11. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478-92
12. Nishimiya K, Matsumoto Y, Takahashi J, Uzuka H, Odaka Y, Nihei T, et al. In vivo visualization of adventitial vasa vasorum of the human coronary artery on optical frequency domain imaging. Validation study. Circ J 2014; 78: 2516-8
13. Hildebrandt HA, Gossl M, Mannheim D, Versari D, Herrmann J, Spendlove D, et al. Differential distribution of vasa vasorum in different vascular beds in humans. Atherosclerosis 2008; 199: 47-54
14. Nishimura RA, Lerman A, Chesebro JH, Ilstrup DM, Hodge DO, Higano ST, et al. Epicardial vasomotor responses to acetylcholine are not predicted by coronary atherosclerosis as assessed by intracoronary ultrasound. J Am Coll Cardiol 1995; 26: 41-9
15. Cassar A, Matsuo Y, Herrmann J, Li J, Lennon RJ, Gulati R, et al. Coronary atherosclerosis with vulnerable plaque and complicated lesions in transplant recipients: new insight into cardiac allograft vasculopathy by optical coherence tomography. Eur Heart J 2013; 34: 2610-7
16. Aoki T, Rodriguez-Porcel M, Matsuo Y, Cassar A, Kwon TG, Franchi F, et al. Evaluation of coronary adventitial vasa vasorum using 3D optical coherence tomography-Animal and human studies. Atherosclerosis 2015; 239: 203-8
17. McManus BM, Horley KJ, Wilson JE, Malcom GT, Kendall TJ, Miles RR, et al. Prominence of coronary arterial wall lipids in human heart allografts. Implications for pathogenesis of allograft arteriopathy. Am J Pathol 1995; 147: 293-308
18. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25
19. O'Brien KD, McDonald TO, Chait A, Allen MD, Alpers CE. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-82
20. Wilson SH, Herrmann J, Lerman LO, Holmes DR Jr, Napoli C, Ritman EL, et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-8
21. Gossl M, Herrmann J, Tang H, Versari D, Galili O, Mannheim D, et al. Prevention of vasa vasorum neovascularization attenuates early neointima formation in experimental hypercholesterolemia. Basic Res Cardiol 2009; 104: 695-706
22. Matsuo Y, Cassar A, Yoshino S, Flammer AJ, Li J, Gulati R, et al. Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation. J Heart Lung Transplant 2013; 32: 784-91